anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain the subject safe composition free from dangers such as explosion of the formation of foams because of no use of propellant and good in the quality of the foams extruded from a foam-extruding container by including a surfactant and a polymeric compound. SOLUTION: This composition comprises (A) 0.01-10 wt.% one or more kinds of surfactants selected from anionic surfactants (e.g. a fatty acid soap), cationic surfactants (e.g. stearyltrimethylammonium chloride), nonionic surfactants (e.g. a polyoxyethylene alkyl ether) and amphoteric surfactants (e.g. a carboxybetaine), (B) a polymeric compound (e.g. hydroxyethylcellulose in such as amount as giving a whole system viscosity of 0.01-10,000 centipoises (cp) and, if necessary, (C) an oil, a water-soluble polyhydric alcohol, a diluent, a medicine, a perfume, a colorant, etc. The composition is charged into a container enabling to mix the composition with air and extrude the mixture as foams.
Epilepsy is a common neurological disorder which can cause significant morbidity and mortality. N6-methyladenosine (m6A), the most common chemical epigenetic modification among mRNA post-transcriptional modifications, implicated in various physiological and pathological processes, but its role in epilepsy is still unknown. Here, we provide strong evidences in support of an association of m6A and its regulatory proteins with epilepsy. Our results indicated that the level of m6A was declined significantly in the dentate gyrus (DG) of hippocampus of pentylenetetrazol (PTZ)-induced seizure mice. Both the seizure-like behaviors and the excessive activation of DG area neuron were significantly mitigated after the administration of m6A agonist betaine. Mechanically, we found that both the m6A methyltransferase METTL14 and recognition protein YTHDC1 were decreased by PTZ stimulation, which might contribute to the reduced m6A level. Additionally, DG-specific over-expression of METTL14 or YTHDC1 by lentivirus injection could significantly ameliorate seizure-like behaviors and prevent the excessive activation of neuron in epilepsy mice induced by PTZ injection, which might be due to the normalized m6A level. Together, this study identified that METTL14/YTHDC1-mediated m6A modification could participate in seizure-like behaviors, which might provide m6A regulation as a potential and novel therapeutic strategy for epilepsy.
This study plans to learn more about radiation therapy. Radiation therapy is one of the main treatments used to treat lung cancer. One of the known side effects of this radiation therapy is scarring of the lungs and reduced lung function that can result in shortness of breath. At this time the radiation treatment plan does not take into account differences in lung function between one part of the lung and another. Studies have shown that lung function can vary substantially throughout the lungs. This study aims to plan the radiation therapy to be away from the highest functioning portions of lungs while still delivering the intended radiation dose to the tumor. This study will allow researchers to determine whether taking lung function information into account when designing radiation treatment plans can protect lung function after radiation therapy.
PURPOSE: To provide a medicine which contains cyclic peptides as effective components, inhibits the interaction of B2 integrin receptor ligands and is useful for the treatment and prevention of the thrombosis, mycocardial infarct, apolexy, atheroarterial scherosis, inflammation, angina pectoris and tumor. CONSTITUTION: At least one of 18 kinds of the cyclic peptides represented by the cyclic formula (-Arg-Gly-Asp-D-phe-Val-Ala) or their salts are incorporated as the effective components at 0.05 to 500 mg, more preferably 0.5 to 100 mg into the compsn. The compsn. may be made into pharmaceuticals in an oral administration form or in the form of a suppository, soln., suspension, ointment, cream, etc. The dose thereof is 0.01 to 2 mg/kg per day. The cyclic peptides inhibit the cell adhesion at the site of osteoclast formation, accelerates vasculogenesis and the adhesion of a wound, further, inhibits the adhesion of the cancer cells and is useful for the treatment and prevention of the osteoporosis as well.
Carcinogenesis — Oral carcinogenicity studies were conducted in mice and rats. Olanzapine was administered to mice in two 78-week studies at doses of 3, 10, 30/20 mg/kg/day (equivalent to 0.8 to 5 times the maximum recommended human daily oral dose on a mg/m2 basis) and 0.25, 2, 8 mg/kg/day (equivalent to 0.06 to 2 times the maximum recommended human daily oral dose on a mg/m2 basis). Rats were dosed for 2 years at doses of 0.25, 1, 2.5, 4 mg/kg/day (males) and 0.25, 1, 4, 8 mg/kg/day (females) (equivalent to 0.13 to 2 and 0.13 to 4 times the maximum recommended human daily oral dose on a mg/m2 basis, respectively). The incidence of liver hemangiomas and hemangiosarcomas was significantly increased in 1 mouse study in female mice at 2 times the daily oral MRHD based on mg/m2 body surface area. These tumors were not increased in another mouse study in females dosed; up to 2 to 5 times the daily oral MRHD based on mg/m2 body surface area in this study, there was a high incidence of early mortalities in males of the 30/20 mg/kg/day group. The incidence of mammary gland adenomas and adenocarcinomas was significantly increased in female mice dosed at ≥2 mg/kg/day and in female rats dosed at ≥4 mg/kg/day (0.5 and 2 times the maximum recommended human daily oral dose on a mg/m2 basis, respectively). Antipsychotic drugs have been shown to chronically elevate prolactin levels in rodents. Serum prolactin levels were not measured during the olanzapine carcinogenicity studies; however, measurements during subchronic toxicity studies showed that olanzapine elevated serum prolactin levels up to 4-fold in rats at the same doses used in the carcinogenicity study. An increase in mammary gland neoplasms has been found in rodents after chronic administration of other antipsychotic drugs and is considered to be prolactin mediated. The relevance for human risk of the finding of prolactin mediated endocrine tumors in rodents is unknown [see Warnings and Precautions (5.15)]. 

Mutagenesis — No evidence of genotoxic potential for olanzapine was found in the Ames reverse mutation test, in vivo micronucleus test in mice, the chromosomal aberration test in Chinese hamster ovary cells, unscheduled DNA synthesis test in rat hepatocytes, induction of forward mutation test in mouse lymphoma cells, or in vivo sister chromatid exchange test in bone marrow of Chinese hamsters. 

Impairment of Fertility — In an oral fertility and reproductive performance study in rats, male mating performance, but not fertility, was impaired at a dose of 22.4 mg/kg/day and female fertility was decreased at a dose of 3 mg/kg/day (11 and 1.5 times the maximum recommended human daily oral dose on a mg/m2 basis, respectively). Discontinuance of olanzapine treatment reversed the effects on male mating performance. In female rats, the precoital period was increased and the mating index reduced at 5 mg/kg/day (2.5 times the daily oral MRHD based on mg/m2 body surface area). Diestrous was prolonged and estrous delayed at 1.1 mg/kg/day (0.6 times the daily oral MRHD based on mg/m2 body surface area); therefore olanzapine may produce a delay in ovulation.
BACKGROUND: The addition of wine lees to diets can make up for the deficiencies caused by traditional forages in beef cattle farming. However, the effects of different wine lees ratios on average daily weight, gastrointestinal microbial community structure and metabolites in Guanling crossbred cattle have been rarely studied. This study assessed the effects of feeds containing wine lees on weight gain, gastrointestinal microbial community structure, and metabolites in Guanling crossbred cattle and elucidated the metabolic responses induced by wine lees. Eighteen cows were randomly assigned to receive fed concentrate (C group), feed containing 15% wine lees (group A), or feed containing 30% wine lees (group B) for 60 days.
RESULTS: The average daily weight gain of group A and group B increased by 76.75% and 57.65%, respectively, compared with group C. Microbial community analysis showed that wine lees increased the abundance of Prevotella_1 in the rumen, decreased the abundance of Ruminococcaceae UCG 011 and Lachnospiraceae_FCS020_group in the rumen, and increased the abundance of Tyzzerella_4, Family_Xlll_AD3011_group, Granulicella, and Eisenbergiella in the cecum. Metabolomics analyses showed that wine lees decreased the concentrations of indole-3-ethanol in the rumen, and complexity cecal metabolism. Notably, linoleic acid metabolism was significantly enriched in both the rumen and cecum. Mantel test analyses indicated that the adverse effects of WL were reduced by stimulating the metabolism of linoleic acid, α-linolenic acid, and tryptophan, and these changes were mediated by intestinal microorganisms. The Guanling cattle cecum was enriched for several unfavorable metabolic pathways when wine lees concentrations reached 30%, which increased the likelihood of intestinal lesions.
CONCLUSION: This study shows that WL supplementation alters gut microbiota and metabolic pathways, improving cattle growth and health. Moderate WL levels (15%) enhance gut health and beneficial pathways (e.g., linoleic and alpha-linolenic acid metabolism). However, higher WL inclusion (30%) may activate adverse pathways, raising the risk of intestinal damage. To maximize benefits and minimize risks, WL levels should be carefully managed.
All interventions will involve 4 weeks of group intervention consisting of two 1-hour group sessions per week and additional practice between sessions. Half of study participants will be randomized to receive 30 minutes of sham transcranial direct current stimulation (tDCS) prior to beginning each ET session. ET session will begin immediately after tDCS. During the sham tDCS, the procedures will be exactly the same as the real tDCS (e.g., application of electrodes), however, no stimulation will be provided when the device turned on.
A pharmaceutical composition (e.g. vaccine) comprising an RNA encoding the SARS-CoV-2 spike protein or an immunogenic fragment or variant thereof. The RNA is formulated in lipid nanoparticles comprising a cationically ionizable lipid, a neutral lipid (e.g. phospholipid), a steroid (e.g. cholesterol), and a polyethylene glycol (PEG)-lipid. The fragment can comprise the receptor binding domain (RBD). The RNA can be modified with a modified uridine residue. The phospholipid can be distearoylphosphatidylcholine (DSPC). The RNA can comprise a 5’ cap, a 5’ UTR, a 3’ UTR, and a polyA sequence. The polyA sequence can comprise at least 100 A nucleotides. The polyA sequence can be interrupted. The 5’ cap is or comprises a cap1 structure. The composition can comprise at least one salt and/or a cryoprotectant. The cryoprotectant can be sucrose. The RNA can be present within a range of 1 µg to 100 µg per dose in the composition. The composition can be used in a method to induce an immune response against coronavirus in a subject (e.g. human). The method can comprise administering a second dose. The second dose can be administered 7 to 28 days following administration of the first dose. The composition can be administered by intramuscular administration.
UNLABELLED: Bleeding tongue-biting episodes during sleep are a rare and alarming situation that can negatively impact the child's and parents' sleep, affecting their quality of life. Although highly suggestive of epilepsy, a differential diagnosis should be made with sleep-related movement disorders such as bruxism, hypnic myoclonus, facio-mandibular myoclonus, and geniospasm when this hypothesis is excluded. The clinical history, electroencephalogram, and video-polysomnography are essential for diagnostic assessment. Treatment with clonazepam can be necessary in the presence of frequent tongue biting that causes severe injuries and sleep disturbance. This study reports the challenging case of managing and diagnosing a 2-year-old boy with recurrent tongue biting during sleep since he was 12 months old, causing bleeding lacerations, frequent awakenings, and significant sleep impairment with daytime consequences for him and his family.
CITATION: Cascais I, Ashworth J, Ribeiro L, Freitas J, Rios M. A rare case of tongue biting during sleep in childhood. J Clin Sleep Med. 2024;20(4):653-656.
A well-known risk of epidural anesthesia may be an unintentional subarachnoid injection of local anesthetic. Two clinical studies have been performed to verify the safety of ropivacaine hydrochloride at a volume of 3 mL injected into the subarachnoid space since this dose represents an incremental epidural volume that could be unintentionally injected. The 15 and 22.5 mg doses injected resulted in sensory levels as high as T5 and T4, respectively. Anesthesia to pinprick started in the sacral dermatomes in 2 to 3 minutes, extended to the T10 level in 10 to 13 minutes and lasted for approximately 2 hours. The results of these two clinical studies showed that a 3 mL dose did not produce any serious adverse events when spinal anesthesia blockade was achieved.

  


During epidural administration, ropivacaine hydrochloride should be administered in incremental doses of 3 to 5 mL with sufficient time between doses to detect toxic manifestations of unintentional intravascular or intrathecal injection. Syringe aspirations should also be performed before and during each supplemental injection in continuous (intermittent) catheter techniques. An intravascular injection is still possible even if aspirations for blood are negative. During the administration of epidural anesthesia, it is recommended that a test dose be administered initially and the effects monitored before the full dose is given. When clinical conditions permit, the test dose should contain an appropriate dose of epinephrine to serve as a warning of unintentional intravascular injection. If injected into a blood vessel, this amount of epinephrine is likely to produce a transient "epinephrine response" within 45 seconds, consisting of an increase in heart rate and systolic blood pressure, circumoral pallor, palpitations and nervousness in the unsedated patient. The sedated patient may exhibit only a pulse rate increase of 20 or more beats per minute for 15 or more seconds. Therefore, following the test dose, the heart should be continuously monitored for a heart rate increase. Patients on beta-blockers may not manifest changes in heart rate, but blood pressure monitoring can detect a rise in systolic blood pressure. A test dose of a short-acting amide anesthetic such as lidocaine is recommended to detect an unintentional intrathecal administration. This will be manifested within a few minutes by signs of spinal block (e.g., decreased sensation of the buttocks, paresis of the legs, or, in the sedated patient, absent knee jerk). An intravascular or subarachnoid injection is still possible even if results of the test dose are negative. The test dose itself may produce a systemic toxic reaction, high spinal or epinephrine-induced cardiovascular effects.
Abstract A dental charting system and method of generating a dental chart are provided. The dental charting system comprises a display unit, an input unit and an output unit. The display unit is configured to display a quadrant view of a set of teeth. The quadrant view comprises a quadrant subset of the set of teeth, and at least one of a diagnosis field and a procedure field for each tooth in the quadrant subset. Each tooth in the quadrant subset displayed having a crown, a root and an outline. The input unit is configured to receive an input for at least one of the diagnosis field and the procedure field for at least one tooth in the quadrant set of teeth. The output unit is configured to generate a dental chart displaying the set of teeth. Each tooth in the set of teeth displayed in a color associated with the received input for at least one of the diagnosis field and the procedure field. The method comprises displaying a quadrant view of a set of teeth, receiving an input for at least one of the diagnosis field and the procedure field for at least one tooth in the quadrant set of teeth, and generating a dental chart displaying the set of teeth. Quadrant View 200b 254 254 252 252 256 258 252 258 258-- AbbreviationRecord 300 Color 360 Abbreviation Category 352 354 Root Crown __ __ __ __ __ __ __ __ __ __ __ __362 364 Medical Description Lay Description Outline Occ. Cr. 356 358 3368
The invention discloses an application of inosine in preparing a medicament for promoting testosterone secretion, and belongs to the technical field of biological medicines. The effective active ingredients of the medicine are only inosine or pharmaceutically acceptable salts thereof. The preparation is in the form of tablet, capsule, oral liquid, buccal preparation, granule, pill, powder, unguent, pellet, suspension, powder or injection. The administration route of the above drugs is oral, transdermal, intramuscular, subcutaneous or intravenous injection. Since inosine exists in a physiological state and can be metabolized and generated by microorganisms existing in the intestinal tract, reasonable supplementation of inosine is a safer and more effective method for restoring testosterone. Inosine is beneficial to maintaining the stable state of intestinal flora, and the experimental result further shows that the inosine can restore the damaged intestinal barrier, so that the intestinal barrier is safer. Moreover, the invention does not directly supplement exogenous testosterone, so that the problems of difficult induction of spermatogenesis disorder, promotion of prostatic hyperplasia and the like are not easy to occur.
At least one compound of Formula I or a pharmaceutically acceptable salt thereof, are provided herein. Pharmaceutical compositions comprising at least one one compound of Formula I or a pharmaceutically acceptable salt and one or more pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to angiogenic kinase modulation, which comprise administering to such patients an amount of at least one compound of Formula I or a pharmaceutically acceptable salt effective to reduce signs or symptoms of the disease or disorder are disclosed. These diseases include cancer, including breast neoplasia, endometrial cancer, colon cancer, and neck squamous cell carcinoma. Methods of treatment include administering at least one compound of Formula I or a pharmaceutically acceptable salt as a single active agent or administering such at least one compound of Formula I or a pharmaceutically acceptable salt in combination with one or more other therapeutic agents. A method for determining the presence or absence of an angiogenic kinase in a sample comprising contacting the sample with at least one compound of Formula I or a pharmaceutically acceptable salt under conditions that permit detection of activity of the angiogenic kinase, detecting a level of the activity of the angiogenic kinase, and therefrom determining the presence or absence of the angiogenic kinase in the sample.
PURPOSE:To provide a make-up cosmetic containing sepiomelanine which is a safe and easily available black pigment. CONSTITUTION:Sepiomelanine (ink of cuttlefish) is compounded to eye-liner, mascara, eyebrow pencil, lipstick, etc. as a black pigment. The sepiomelanine can be easily obtained in high yield, by taking out from an inkbag of cuttlefish, washing or dialysing with water, and drying. It is indolemelanine having a composition extremely close to that of the melanine of the human hair, and is free of primary stimulation, sensitization, photo-toxicity, and photo-sensitization. Since it is composed of animal proteins, it has moderate hydrophilic charactieristics, and is easily dispersed in water compared with the other inorganic pigments. Especially suitable to use as a liquid-type eye-liner or an eyebrow pencil.
A nanoparticle comprises a metal nanoparticle, e.g. gold, functionalised with at least one linker, the at least one linker comprising at least one first moiety capable of interacting with the metal nanoparticle, and at least one second moiety capable of interacting with at least one platinum group metal-based biologically active compound, e.g. a drug, wherein the molar ratio or capacity of platinum group metal-based biologically active compounds per nanoparticle is greater than (150). The present invention also relates to a method of preparing a nanoparticle according to the present invention. The present invention also relates to a biologically active nanoparticle comprising a nanoparticle according to the present invention, and at least one platinum group metal-based biologically active compound. The biologically active nanoparticle is more efficiently targeted to specific parts of the body, e.g. cancer cells, while reducing the side effects of the biomolecules being delivered.
Methods, systems, and devices for wireless communications are described. A functionality that enables wireless devices to use a proximity service provided by a network may be activated in an emergency situation. The network may configure a set of wireless devices to broadcast codes that protect the privacy of the broadcasting devices. The network may configure another set of wireless devices to monitor and catalogue such codes broadcasted by other wireless devices. The catalogued codes may be reported to the network. The network may obtain a set of codes broadcasted by a wireless device and compare the set of codes with a database of codes stored by the network to determine which wireless devices in the network have come into close contact with the wireless device.
TDF, a component of efavirenz, lamivudine and tenofovir disoproxil fumarate tablets is principally eliminated by the kidney. Renal impairment, including cases of acute renal failure and Fanconi syndrome (renal tubular injury with severe hypophosphatemia), has been reported with the use of TDF [see Adverse Reactions (6.2)].

Prior to initiation and during use of efavirenz, lamivudine and tenofovir disoproxil fumarate, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients.

Avoid efavirenz, lamivudine and tenofovir disoproxil fumarate with concurrent or recent use of a nephrotoxic agent (e.g., high-dose or multiple non-steroidal anti-inflammatory drugs (NSAIDs)) [see Drug Interactions (7.3)]. Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in HIV-infected patients with risk factors for renal dysfunction who appeared stable on TDF. Some patients required hospitalization and renal replacement therapy. Alternatives to NSAIDs should be considered, if needed, in patients at risk for renal dysfunction.

  


Persistent or worsening bone pain, pain in extremities, fractures and/or muscular pain or weakness may be manifestations of proximal renal tubulopathy and should prompt an evaluation of renal function in patients at risk of renal dysfunction.
The study is non-interventional as there are no interventions involved and the decision to initiate oral semaglutide treatment is at the discretion of the treating physician and is clearly independent from the decision to include the participant in the study. Participants will be treated with oral semaglutide (at least 4 weeks on maintenance dose) once daily with or without other oral antidiabetics (OADs) as per local label at the discretion of the treating physician.
A pretest was administered to the experimental group. Then, 360-degree VR videos (nature walks, trips, etc.) were watched three days a week for four weeks. Then, the final test was administered.As a result, caregivers' care burden and psychological well-being will be measured.